293 related articles for article (PubMed ID: 1469405)
21. [Acetylcholinesterase activity in CSF in senile dementia of Alzheimer type, vascular dementia, and Parkinson's disease].
Yoshinaga J; Sasaki T; Ideshita H; Hikiji A; Kuwaki T
Rinsho Shinkeigaku; 1989 Mar; 29(3):376-8. PubMed ID: 2752667
[TBL] [Abstract][Full Text] [Related]
22. Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in Alzheimer's disease.
Sáez-Valero J; Small DH
Brain Res; 2001 Jan; 889(1-2):247-50. PubMed ID: 11166713
[TBL] [Abstract][Full Text] [Related]
23. Cholinesterases in cerebrospinal fluid. Correlations with clinical measures in Alzheimer's disease.
Huff FJ; Maire JC; Growdon JH; Corkin S; Wurtman RJ
J Neurol Sci; 1986 Feb; 72(2-3):121-9. PubMed ID: 3711929
[TBL] [Abstract][Full Text] [Related]
24. Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia.
Wallin A; Sjögren M; Blennow K; Davidsson P
Dement Geriatr Cogn Disord; 2003; 16(4):200-7. PubMed ID: 14512714
[TBL] [Abstract][Full Text] [Related]
25. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
[TBL] [Abstract][Full Text] [Related]
26. Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers of Alzheimer's disease.
Sáez-Valero J; Small DH
J Alzheimers Dis; 2001 Jun; 3(3):323-328. PubMed ID: 12214053
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
Zubenko GS; Marquis JK; Volicer L; Direnfeld LK; Langlais PJ; Nixon RA
Biol Psychiatry; 1986 Dec; 21(14):1365-81. PubMed ID: 3024746
[TBL] [Abstract][Full Text] [Related]
28. The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.
Petzer A; Harvey BH; Petzer JP
Toxicol Appl Pharmacol; 2014 Feb; 274(3):488-93. PubMed ID: 24161345
[TBL] [Abstract][Full Text] [Related]
29. Molecular forms of acetylcholinesterase and butyrylcholinesterase in human plasma and cerebrospinal fluid.
Atack JR; Perry EK; Bonham JR; Perry RH
J Neurochem; 1987 Jun; 48(6):1845-50. PubMed ID: 3572402
[TBL] [Abstract][Full Text] [Related]
30. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease.
Ruberg M; Rieger F; Villageois A; Bonnet AM; Agid Y
Brain Res; 1986 Jan; 362(1):83-91. PubMed ID: 3942870
[TBL] [Abstract][Full Text] [Related]
31. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease.
Darreh-Shori T; Vijayaraghavan S; Aeinehband S; Piehl F; Lindblom RP; Nilsson B; Ekdahl KN; Långström B; Almkvist O; Nordberg A
Neurobiol Aging; 2013 Nov; 34(11):2465-81. PubMed ID: 23759148
[TBL] [Abstract][Full Text] [Related]
32. Acetylcholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type.
Soininen H; Halonen T; Riekkinen PJ
Acta Neurol Scand; 1981 Sep; 64(3):217-24. PubMed ID: 7315192
[TBL] [Abstract][Full Text] [Related]
33. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate.
Unni L; Vicari S; Moriearty P; Schaefer F; Becker R
Methods Find Exp Clin Pharmacol; 2000; 22(1):57-61. PubMed ID: 10791297
[TBL] [Abstract][Full Text] [Related]
34. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
35. Acetyl- and butyrylcholinesterase activity in the cerebrospinal fluid of patients with Parkinson's disease.
Sirviö J; Soininen HS; Kutvonen R; Hyttinen JM; Helkala EL; Riekkinen PJ
J Neurol Sci; 1987 Nov; 81(2-3):273-9. PubMed ID: 3694232
[TBL] [Abstract][Full Text] [Related]
36. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Mushtaq G; Greig NH; Khan JA; Kamal MA
CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.
Atack JR; Litvan I; Thal LJ; May C; Rapoport SI; Chase TN
J Neurol Neurosurg Psychiatry; 1991 Sep; 54(9):832-5. PubMed ID: 1955905
[TBL] [Abstract][Full Text] [Related]
38. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
Kennedy JS; Polinsky RJ; Johnson B; Loosen P; Enz A; Laplanche R; Schmidt D; Mancione LC; Parris WC; Ebert MH
J Clin Psychopharmacol; 1999 Dec; 19(6):513-21. PubMed ID: 10587286
[TBL] [Abstract][Full Text] [Related]
39. CSF acetylcholinesterase in dementia and in sequential samples of lumbar CSF.
Lal S; Wood PL; Kiely ME; Etienne P; Gauthier S; Stratford J; Ford RM; Dastoor D; Nair NP
Neurobiol Aging; 1984; 5(4):269-74. PubMed ID: 6531064
[TBL] [Abstract][Full Text] [Related]
40. CSF choline and acetylcholinesterase in early-onset vs. late-onset Alzheimer's disease patients.
Kumar V; Giacobini E; Markwell S
Acta Neurol Scand; 1989 Nov; 80(5):461-6. PubMed ID: 2589014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
